AlphAIAlphAI — Financial news for AI agents
investing.com$CADL

Why is Candel Therapeutics stock collapsing today?

Candel Therapeutics (CADL) stock fell 36.7% to $5.31 in pre-market trading after delaying its Biologics License Application submission for aglatimagene besadenovec to mid-2027, citing FDA discussions and assay refinement. The company reported a Q3 2026 net loss of $21.9 million, nearly double the previous year's loss, and announced a $50 million stock sale agreement. Analysts reduced price targets, with Stifel cutting to $19 and Canaccord to $13, both maintaining Buy ratings.

Original reporting
investing.com
Published Nov 13, 2026, 1:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 2:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$CADL
Bearish
high confidence
Mentioned
$CADL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CADLBearishHigh
01

Why it matters

The combined regulatory delay and dilutive financing raise have triggered a sharp sell‑off, indicating heightened short‑term risk.

02

Market read

The news directly caused a 36.7% pre‑open decline, making it a high‑impact, actionable event for traders.

03

What to watch

Potential partnership or licensing opportunities for the prostate cancer candidate are not discussed.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Candel Therapeutics is a clinical‑stage biopharma focused on localized prostate cancer therapies.

Company-level read

Ticker impact

$CADLBearishHigh confidence
Context

Candel Therapeutics announced a six‑month delay of its BLA filing and a $50 million at‑the‑market stock sale, causing a 36.7% pre‑open drop.

Expected impact

likely pressure as the market prices in the delayed filing and dilution concerns

Evidence & confidence

Both the regulatory setback and new equity issuance are fresh, material facts that triggered a sharp sell‑off.

Market effects

Sector

Biotech sector may see heightened scrutiny on timelines for BLA submissions, pressuring peers with similar pipelines.

Regional

US biotech indices could dip slightly as investors reassess regulatory risk.

Global

Limited to US‑listed biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the delay reflects a strategic decision to ensure data quality, the long‑term upside could remain intact.

Key entities

  • company
    Candel Therapeutics

    Clinical‑stage biopharma issuing the news.

  • financial_institution
    Jefferies

    Underwriter of the $50 million at‑the‑market stock sale.

Read at source← All news

StoryCandel Therapeutics posts larger Q3 loss, outlines mid‑2027 BLA filing

Also covered by

3 outlets

Related articles

$CADLMed

Candel Therapeutics Outlines Mid-2027 BLA Plan For Aglatimagene Following Q3 Results

Candel Therapeutics (CADL) reported a wider Q3 2026 net loss of $21.9M, up from $11.3M a year ago, due to increased R&D and G&A expenses. The company plans to submit a BLA for aglatimagene in localized prostate cancer in mid-2027, pending FDA discussions. Cash reserves total $203.1M, expected to last into Q2 2028. Clinical updates include positive Phase 2 and 3 data for aglatimagene in prostate cancer and NSCLC, and ongoing Phase 3 AURORA trial.

rttnews.com
$CADLHigh

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Candel Therapeutics (CADL) stock fell 38% after-hours after pushing back its FDA application for prostate cancer treatment to mid-2027. The company reported $203.1M in cash, expected to last until Q2 2028. Retail traders on Stocktwits remained bullish, with some suggesting the selloff could make the stock more attractive. CADL is up 48.5% year-to-date, according to the article.

finance.yahoo.com
$CADLMed

Candel Therapeutics, Inc. entered into a Second Amended and Restated Open Market Sale Agreement SM, with Jefferies LLC, to sell shares of the Company’s…

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale Agreement SM (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value

SEC EDGAR 8-K
$CADLHigh

Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights • The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines

SEC EDGAR 8-K